Skip to main content
. 2021 May 31;34(5):1289–1300. doi: 10.1007/s13577-021-00560-w

Fig. 2.

Fig. 2

Approved Mesenchyme Stromal Cells (MSCs) based products for treatment Refectory Crohn´s disease (CD)